Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ex-Takeda CEO Weber Joins Rakuten Medical as Vice Chairman
Rakuten Medical said on September 10 that former Takeda Pharmaceutical CEO Christophe Weber has joined its board as vice chairman as the biotech beefs up its leadership ranks to drive its R&D and US commercialization plans for its photoimmunotherapy platform.…
To read the full story
Related Article
- Roche Proposes Ex-Takeda CEO Weber for Board
September 24, 2026
- Rakuten Medical CEO-Elect Reaffirms 2028 US Filing Plan for Akalux
June 15, 2026
BUSINESS
- Asahi Kasei Rebrands Pharma Units under Common Global Name
September 30, 2026
- Chugai Licenses RAF-MEK Molecular Glue to InxMed
September 30, 2026
- OB-GYN Chief Hopes for April 2027 NIP Addition of RSV Antibodies
September 30, 2026
- KM Biologics Eyes Plasma Product Capacity Expansion with Govt Backing
September 30, 2026
- Japan Needs to Boost COVID Vaccine Uptake, Expert Says
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…